Pure Bioscience, Inc. financial data

Symbol
PURE on OTC
Industry
Miscellaneous Chemical Products
Location
771 Jamacha Road #512, El Cajon, CA
State of incorporation
DE
Fiscal year end
July 31
Former names
PURE BIOSCIENCE (to 3/17/2011), INNOVATIVE MEDICAL SERVICES (to 9/2/2003)
Latest financial report
10-K - Q2 2024 - Oct 29, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 170 % -50.9%
Quick Ratio 11.2 % -62.5%
Debt-to-equity -176 %
Return On Equity 200 %
Return On Assets -264 % -64.6%
Operating Margin -163 % +22.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 112M shares 0%
Common Stock, Shares, Outstanding 112M shares 0%
Entity Public Float 7.35M USD +49.7%
Common Stock, Value, Issued 1.12M USD 0%
Weighted Average Number of Shares Outstanding, Basic 112M shares +0.41%
Weighted Average Number of Shares Outstanding, Diluted 112M shares +0.41%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.96M USD +4.49%
Revenue from Contract with Customer, Excluding Assessed Tax 1.96M USD +4.58%
Research and Development Expense 302K USD +1.68%
Operating Income (Loss) -3.19M USD +19.1%
Nonoperating Income (Expense) -159K USD -783%
Net Income (Loss) Attributable to Parent -3.35M USD +15.4%
Earnings Per Share, Basic -0.03 USD/shares +25%
Earnings Per Share, Diluted -0.03 USD/shares +25%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 349K USD -68.1%
Accounts Receivable, after Allowance for Credit Loss, Current 298K USD +4.56%
Inventory, Net 56K USD -36.4%
Assets, Current 805K USD -49.8%
Property, Plant and Equipment, Net 13K USD -94.1%
Assets 818K USD -55.2%
Accounts Payable, Current 601K USD +42.4%
Accrued Liabilities, Current 132K USD +20%
Liabilities, Current 733K USD +37.8%
Liabilities 3.68M USD +137%
Retained Earnings (Accumulated Deficit) -137M USD -2.51%
Stockholders' Equity Attributable to Parent -2.86M USD -1153%
Liabilities and Equity 818K USD -55.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -440K USD +51.2%
Net Cash Provided by (Used in) Financing Activities 785K USD
Net Cash Provided by (Used in) Investing Activities -37K USD +31.5%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 112M shares 0%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 345K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 424K USD -63.8%
Deferred Tax Assets, Valuation Allowance 29.3M USD -3.33%
Deferred Tax Assets, Gross 29.3M USD -3.33%
Payments to Acquire Property, Plant, and Equipment 37K USD -31.5%
Property, Plant and Equipment, Gross 1.62M USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 26.8M USD -4.82%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 133M USD +0.16%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 80K USD +27%
Interest Expense 111K USD +1133%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%